Malet F, Colin J, Jauch A, Abalain M L
Service Daviel (Ophtalmologie), Centre Hospitalier Régional et Universitaire de Brest, France.
Ophthalmic Res. 1995;27(6):322-9. doi: 10.1159/000267743.
Lomefloxacin is known to have an excellent corneal penetration. The therapeutic effect of two specific treatment regimens with lomefloxacin 0.3% eye drops was studied in a Pseudomonas aeruginosa-induced keratitis model in guinea pigs. An initial loading dose of 1 drop every 5 min for 5 times was used in all groups. Its purpose was to obtain high bactericidal corneal levels in the two actively treated groups. The follow-up treatment for 7 days was by a twice daily regimen in one group and 3 times daily in the other treated group. There were two control groups - one with no treatment and the other with vehicle treatment (initial loading dose followed by twice daily regimen). Clinical signs of cornea, conjunctiva and eye adnexae improved significantly within 2 days in both lomefloxacin regimens, whereas clinical signs deteriorated with vehicle treatment. Fifty percent of the animals treated with lomefloxacin showed no colonies in the swab culture after 2 days of therapy, while all vehicle-treated animals were positive even at day 6, with 5 out of 9 animals continuing to be positive at day 8. Pseudomonas in the range of 100-2,300 colonies was isolated from the grounded and cultured cornea at the end of the study in 4 out of 9 vehicle-treated animals but in none of the lomefloxacin-treated guinea pigs. The biggest difference in the degree of secondary inflammation between lomefloxacin and vehicle-treated groups was observed in the cornea which was the target tissue of infection. An unexpected observation was the lower degree of corneal inflammation in the twice daily treated animals when compared to the 3 times daily treatment group. This finding may be due to the somewhat lower initial degree of corneal inflammation in this group and suggests that the course of corneal recovery is predominately dependent on the initial degree of infection with both dosage regimens of lomefloxacin capable of eradicating corneal organisms.
洛美沙星具有出色的角膜穿透性。在豚鼠铜绿假单胞菌诱导的角膜炎模型中,研究了两种使用0.3%洛美沙星滴眼液的特定治疗方案的治疗效果。所有组均采用初始负荷剂量,每5分钟滴1滴,共滴5次。其目的是在两个积极治疗组中获得高杀菌角膜水平。一组后续7天的治疗方案为每日2次,另一治疗组为每日3次。有两个对照组,一组不治疗,另一组采用赋形剂治疗(初始负荷剂量后每日2次方案)。两种洛美沙星治疗方案在2天内角膜、结膜和眼附属器的临床症状均有显著改善,而赋形剂治疗的临床症状则恶化。接受洛美沙星治疗的动物中有50%在治疗2天后拭子培养中无菌落,而所有接受赋形剂治疗的动物即使在第6天仍为阳性,9只动物中有5只在第8天仍为阳性。在研究结束时,9只接受赋形剂治疗的动物中有4只从研磨并培养的角膜中分离出100 - 2300个菌落的铜绿假单胞菌,而接受洛美沙星治疗的豚鼠均未分离出。在作为感染靶组织的角膜中,观察到洛美沙星组和赋形剂治疗组之间继发性炎症程度的最大差异。一个意外的观察结果是,与每日3次治疗组相比,每日2次治疗的动物角膜炎症程度较低。这一发现可能是由于该组角膜炎症的初始程度略低,表明角膜恢复过程主要取决于初始感染程度,两种洛美沙星给药方案均能根除角膜微生物。